Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01380782 · ClinicalTrials.gov registry record · Phase 2
BIBF 1120 for Recurrent High-Grade Gliomas
A Phase 2 study, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01380782 is a Phase 2 study that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 37 participants.
The verdict
NCT01380782, a Phase 2 study, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies suggests that this agent, BIBF 1120, may help to stop recurrent malignant glioma cells from multiplying and it may also prevent the growth of new blood vessels at the site of the tumor. In this research study, the investigators are looking to see how well BIBF 1120 works in patients with recurrent malignant gliomas.
Interventions
- DRUG BIBF 1120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01380782
The ClinicalTrials.gov registry entry for NCT01380782 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIBF 1120 is the first listed.
NCT01380782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01380782 about?
NCT01380782 is a clinical study titled "BIBF 1120 for Recurrent High-Grade Gliomas". BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies suggests that this agent, BIBF 1120, may help to stop recurrent malignan...
What is the current status of trial NCT01380782?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2012-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01380782?
The interventions under investigation include: BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT01380782?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.